Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and Her-2/Neu oncoprotein expression. Preliminary results

P. J. Van Diest, J. P A Baak, P. Matze-Cok, S. S. Bacus

Research output: Contribution to journalArticlepeer-review

Abstract

The value of morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression for prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients was evaluated in a group of CMF treated patients and controls with long-term follow-up. In the treated group, the Morphometric Prognostic Index (cutpoint 1.1) was the best prognosticator (p

Original languageEnglish (US)
Pages (from-to)344-349
Number of pages6
JournalPathology Research and Practice
Volume188
Issue number3
StatePublished - 1992
Externally publishedYes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and Her-2/Neu oncoprotein expression. Preliminary results'. Together they form a unique fingerprint.

Cite this